FOLH1 and prostate cancer: We might be inclined to initiate drive towards metastatic bone burden reporting—say, in the case of 223Ra-Cl2 and 177Lu-PSMA (177Lu-labelled prostate-specific membrane antigen) for prostate cancer—such that we can monitor the whole disease prior to and following radionuclide therapy.